- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
BioForce Nanosciences, Inc., the leading developer of nanoarray biomolecular analysis systems, announced today that a $2,000,000 total equity investment has been received from the Private Equity team of Société Genérale Asset Management, Paris, France, for the first round of financing.
Dr. Gary A. Alianell, CEO and President of BioForce Nanosciences announced the receipt of funds today. Dr. Alianell states, “We are most pleased with the additional investment by SGAM. Their policy of investing in leading edge technologies lends itself well to BioForce’s mission. We hope to become their leading portfolio company”. BioForce has attracted many investors and anticipates closing the first round by year-end. Midori Yokoyama, Ph.D., Biotech Partner of SGAM, reported that, “BioForce Nanosciences offers very promising technology with near-term products that have superior market potential. We look forward to a successful future.”
BioForce technology is revolutionizing the molecular analysis market. The Company has developed proprietary, ultraminiaturized nanoarrays that permit a vast reduction in the amount of materials necessary for screening. Molecules are placed on solid surfaces at defined locations in the micron and submicron spatial scale. With unique NanoArrays™, thousands of bioaffinity tests can be performed in the area occupied by a single microarray spot. Moreover, the tremendous reduction in assay size evident in nanoarrays creates opportunities for novel applications and implementation of ultrasensitive, label-free and PCR-less readout methods such as Atomic Force Microscopy.
If you have a comment, please
|The latest news from around the world, FREE|
Only the news you want to read!
University Technology Transfer & Patents
Full-service, expert consulting